[HTML] springer.comFull View

[HTML][HTML] Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy

Q Li, Z Li, T Luo, H Shi - Molecular biomedicine, 2022 - Springer
Abstract The PI3K/AKT/mTOR and RAF/MEK/ERK pathways are commonly activated by
mutations and chromosomal translocation in vital targets. The PI3K/AKT/mTOR signaling …
被引用次数：54 相关文章
[HTML] nih.gov

[HTML][HTML] Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy

Q Li, Z Li, T Luo, H Shi - Molecular Biomedicine, 2022 - ncbi.nlm.nih.gov
Abstract The PI3K/AKT/mTOR and RAF/MEK/ERK pathways are commonly activated by
mutations and chromosomal translocation in vital targets. The PI3K/AKT/mTOR signaling …

Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy

Q Li, Z Li, T Luo, H Shi - Molecular biomedicine, 2022 - pubmed.ncbi.nlm.nih.gov
The PI3K/AKT/mTOR and RAF/MEK/ERK pathways are commonly activated by mutations
and chromosomal translocation in vital targets. The PI3K/AKT/mTOR signaling pathway is …

Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy.

Q Li, Z Li, T Luo, H Shi - Molecular Biomedicine, 2022 - europepmc.org
Abstract The PI3K/AKT/mTOR and RAF/MEK/ERK pathways are commonly activated by
mutations and chromosomal translocation in vital targets. The PI3K/AKT/mTOR signaling …

Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy

Q Li, Z Li, T Luo, H Shi - Molecular Biomedicine, 2022 - search.proquest.com
Abstract The PI3K/AKT/mTOR and RAF/MEK/ERK pathways are commonly activated by
mutations and chromosomal translocation in vital targets. The PI3K/AKT/mTOR signaling …

Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy.

Q Li, Z Li, T Luo, H Shi - Molecular Biomedicine, 2022 - europepmc.org
The PI3K/AKT/mTOR and RAF/MEK/ERK pathways are commonly activated by mutations
and chromosomal translocation in vital targets. The PI3K/AKT/mTOR signaling pathway is …